Yew Bio-Pharm Group, Inc. Stocks

$ 0Last Updated 23.03.2026

Issuer Rating

1/7
Performance

Poor

Risk

High

Recommendation

Sell

Market Cap

$ 11838

Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 0
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Yew Bio-Pharm Group, Inc., through its subsidiaries, grows and sells yew trees in the People's Republic of China and the United States. It offers traditional Chinese medicine (TCM) raw materials in the form of yew tree branches and leaves to manufacture TCM containing taxol. The company is also involved in processing and selling yew raw materials used in the manufacture of traditional Chinese medicine; growing and selling yew tree seedlings and mature trees, including potted miniature yew trees; manufacturing and selling furniture and handicrafts made of yew tree timber; selling agricultural products, such as yew candles, pine needle extracts, taxus cuspidate extracts, northeast yew extracts, and yew essential oil soaps; and selling wood ear mushroom. In addition, it engages in the marketing and sale of cosmetics. The company was incorporated in 2007 and is based in El Monte, California.

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITDA

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks